Therapeutic combination compositions and methods of using same
The present invention encompasses a therapeutic combination composition of a β-glucan EGF receptor antagonist. This therapeutic combination composition is useful for the treatment of diseases including proliferative disorders and immune dysfunction.
1 . A composition comprising a β-glucan and an EGF receptor antagonist.
2 . The composition of claim 1 , wherein the β-glucan forms a triple helix.
3 . The composition of claim 2 , wherein the triple helix β-glucan forms a higher order aggregate.
4 . The composition of claim 3 , wherein the higher order aggregate has an aggregate number selected from the group consisting of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20.
5 . The composition of claim 1 , wherein the EGF receptor antagonist is an antibody.
6 . The composition of claim 5 , wherein the antibody is one of polyclonal, monoclonal or a combination thereof.
7 . The composition of claim 6 , wherein the monoclonal antibody is antibody 108 or antibody 96.
8 . The composition of claim 5 , wherein the antibody is Cetuximab.
9 . The composition of claim 1 , further comprising an anti-cancer drug.
10 . The composition of claim 9 , wherein the anti-cancer drug is a member of the group consisting of ironotecan, doxorubicin and cisplatin.
11 . The composition of claim 1 , wherein the composition is administered to a subject.
12 . The composition of claim 11 , wherein the subject is a mammal.
13 . A kit comprising a therapeutic dose of a β-glucan and a therapeutic dose of an EGF receptor antagonist either in the same or separate packaging, and instructions for its use.
14 . The kit of claim 13 , wherein the β-glucan forms a triple helix.
15 . The kit of claim 14 , wherein the triple helix β-glucan forms a higher order aggregate.
16 . The kit of claim 13 , wherein the EGF receptor antagonist is an antibody.
17 . The kit of claim 16 , wherein the antibody is Cetuximab.
18 . A pharmaceutical composition comprising a β-glucan and an EGF receptor antagonist in an effective amount to treat one of cancer, infection or both.
19 . The pharmaceutical composition of claim 18 , wherein the β-glucan is a triple helical β-glucan and the EGF receptor antagonist is Cetuximab.
20 . The pharmaceutical composition of claim 19 , further comprising an anti-cancer drug in an effective amount to treat cancer.